Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical analysis

Neuroscience

Volumn 79, Issue 2, 1997, Pages 497-507

  Goulet, M ^a   Morissette, M ^a,b   Calon, F ^a   Blanchet, P J ^a,b   Falardeau, P ^a   Bedard P J ^a,b   Di Paolo, T ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Dopamine receptors; Dyskinesia; mRNA; Parkinson; Sensitization; Tolerance

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; MESSENGER RNA; U 91356A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; DYSKINESIA; FEMALE; GENE EXPRESSION; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIZATION; SUBCUTANEOUS DRUG ADMINISTRATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMINOQUINOLINES; ANIMALS; DOPAMINE AGONISTS; FEMALE; GENE EXPRESSION; IMIDAZOLES; IN SITU HYBRIDIZATION; MACACA; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TIME FACTORS;

EID: 0030909146     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00689-6     Document Type: Article

References (54)

1. Alexander G. M., Schwartzman R. J., Grothusen J. R., Brainard L. and Gordon S. W. (1993) Change in brain dopamine receptor in MPTP parkinsonian monkeys following L-DOPA treatment. Brain Res. 625, 276-282.
2. 2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Molec. Brain. Res. 11, 161-166.
3. Barbeau A. (1980) High level levodopa therapy in several akinetic parkinsonian patients: twelve years later. In Parkinson's Disease; Current Progress, Problems and Managements (eds Rinne V. K., Klinger M. and Stamm G.), pp. 229-239. Elsevier, Amsterdam.
4. 2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmac. exp. Ther. 272, 854-859.
5. 3H]Spiperone binding, dopamine and HVA concentrations in parkinson's disease and supranuclear palsy. Eur. J. Pharmac. 99, 167-175.
6. 2 agonist in MPTP-treated primates: functional implication for Parkinson disease. Neurology 40, 927-933.
7. 1 dopamine receptors. Neuroscience 67, 37-48.
8. Brené S., Herrera-Marschitz M., Persson H. and Lindefors N. (1994) Expression of mRNAs encoding dopamine receptors in striatal regions is differentially regulated by midbrain and hippocampal neurons. Molec. Brain Res. 21, 274-282.
9. Brené S., Lindefors N., Herrera-Marschitz M. and Persson H. (1990) Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen. Expl Brain Res. 83, 96-104.
10. A receptors in the striatopallidal complex. Brain Res. 680, 43-52.
11. Carlson J. H., Bergstrom D. A., Demo S. D. and Walters J. R. (1990) Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus. Synapse 5, 83-93.
12. 5 receptors mRNAs in the monkey brain: ribonuclease protection assay analysis. Molec. Brain Res. 31, 86-94.
13. 2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat. Molec. Brain Res. 19, 318-322.
14. Dearry A., Falardeau P., Shores C. and Caron M. G. (1991) D2 dopamine receptors in the human retina: cloning of cDNA and localization of mRNA. Cell. molec. Neurobiol. 11, 437-453.
15. 1 dopamine receptor. Nature 347, 72-76.
16. Di Paolo T., Bédard P. J., Daigle M. and Boucher R. (1986) Long-term effects of MPTP on central and peripheral catecholamine and indolamine concentrations in monkeys. Brain Res. 379, 286-293.
17. Engber T. M., Susel Z., Kuo S. and Chase T. N. (1990) Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization. J. Neurosci. 10, 3389-3895.
18. Falardeau P., Bouchard S., Bédard P. J., Boucher R. and Di Paolo T. (1988) Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP-monkeys. Eur. J. Pharmac. 150, 59-66.
19. Gagnon C., Bédard P. J. and Di Paolo T. (1990) Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur. J. Pharmac. 178, 115-120.
20. A receptors. Neurosci. Lett. 163, 31-35.
21. Gagnon C., Gomez-Mancilla B., Markstein R., Bédard P. J. and Di Paolo T. (1995) Effect of adding the D1 agonist CY208243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors. Prog. Neuropsychopharmac. biol. Psychiat. 19, 667-676.
22. Gancher S. T., Nutt J. G. and Woodward W. R. (1995) Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance. Movement Disord. 10, 37-43.
23. 2 dopamine receptor regulation of striatonigral and striatopallidal neurons. Semin. Neurosci. 4, 109-118.
24. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
25. Goldman-Rakic P. S. (1992) Dopamine-mediated mechanisms of the prefrontal cortex. Semin. Neurosci. 4, 149-159.
26. 2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 602, 290-303.
27. 2 dopamine receptor in Parkinson's diseased striatum. J. neural Transm. 64, 93-104.
28. 3H]dopamine: distribution, regulation and relationship to coupling. Neuroscience 46, 687-700.
29. Jongen-Relo A. L., Docter G. J., Jonker A. J., Vreugdenhil E., Groenewegen H. J. and Voorn P. (1994) Differential effects of dopamine depletion on the binding and mRNA levels of dopamine receptors in the shell and core of the rat nucleus accumbens. Molec. Brain Res. 25, 333-343.
30. Koller W. C. and Hubble J. P. (1990) Levodopa therapy in Parkinson's disease. Neurology 40, 40-50.
31. 1 dopamine receptor gene. Molec. Pharmac. 41, 652-659.
32. Marsden C. D. (1992) Dopamine and basal ganglia disorders in humans. Semin. Neurosci. 4, 171-178.
33. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D., Sambrook M. A. and Crossman A. R. (1989) Neural mechanism underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32, 213-226.
34. Mouradian M. M., Heuser I. J. E., Baronti F. and Chase T. N. (1990) Modification of central dopaminergic mechanism by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27, 18-23.
35. Mouradian M. M., Heuser I. J. E., Baronti F., Fabbrini G., Juncos J. L. and Chase T. N. (1989) Pathogenesis of dyskinesia in Parkinson's disease. Ann. Neurol. 25, 523-526.
36. 2 dopamine mRNA after denervation. Proc. natn. Acad. Sci. U.S.A. 88, 2802-2806.
37. Nutt J. G. (1990) Levodopa induced dyskinesia: review, observations, and speculation. Neurology 40, 340-345.
38. Pan H. S. and Walters J. R. (1988) Unilateral lesion of the nigrostriatal pathway decreases firing rate and alters the firing pattern of globus pallidus neurons in the rat. Synapse 2, 650-659.
39. Parent A. (1990) Extrinsic connection of the basal ganglia. Trends Neurosci. 13, 254-258.
40. 1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur. J. Pharmac. 114, 235-237.
41. Post R. M. (1980) Intermittent versus continuous stimulation: Effect of time interval on the development of sensitization or tolerance. Life Sci. 2, 1275-1282.
42. 2 dopamine receptors. J. Neurochem. 62, 411-420.
43. 5 receptor mRNA in monkey striatum. Brain Res. 616, 242-250.
44. 1 receptors in the parkinsonian brain. Brain Res. 359, 306-310.
45. Schneider J. S. (1989) Levodopa-induced dyskinesia in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmac. Biochem. Behav. 34, 193-196.
46. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1, 5-15.
47. 2 receptors in Parkinson's disease and striatonigral degeneration determined by PET. Adv. Neurol. 60, 488-492.
48. Szabo J. and Cowan W. M. (1984) A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. comp. Neurol. 222, 265-300.
49. Vaamonde J., Luquin M. R. and Obeso J. A. (1991) Subcutaneous lisuride infusion in Parkinson's disease: Response to chronic administration in 34 patients. Brain 144, 601-614.
50. Weiss B., Cimino M., Winkler J. D. and Chen J. F. (1989) Behavioral, biochemical and molecular biological correlates of modulating dopaminergic responses. Neurochemical Pharmacology - A Tribute to B. B. Brodie pp. 149-164, Raven Press, New York.
51. 2 dopamine receptor mRNA in mouse brain: molecular and behavioral correlates. Adv. Biosci. 77, 9-25.
52. Wooten G. F. and Collins R. C. (1983) Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesions. Brain Res. 263, 267-275.
53. 2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sci. 50, 383-396.
54. Young W. S. III, Bonner T. I. and Brann M. R. (1986) Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. natn. Acad. Sci. U.S.A. 83, 9827-9831.